Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Their proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies…More, with multiple INDs open. They use these therapies to harness the body's own immune system to find and destroy diseased cells. Their SPEAR TCR therapies offer promise to patients that often have no other options. They are working hard to make that promise a reality.